NADAV Technology

ViruCure is developing the NADAV technology, a robust oncolytic-virus-based platform, for the treatment of a wide range of cancers.

Harnessing NADAV’s natural cancer fighting ability

ViruCure’s NADAV platform utilizes proprietary Newcastle Disease Virus (NDV) strains.

NADAV is a virus that causes different levels of infections in many kinds of birds. Yet in over 40 years of research, NADAV virus strains were found not to exhibit any pathological effects or severe illnesses in humans.  This combined with its high selectivity to replicate much faster in human cancer cells than normal human cells beyond the initial therapeutic dose, suggests the NADAV technology could be a breakthrough treatment modality as a highly safe and effective cancer therapy.

NADAV technology: Dual-acting mechanism of action

The NADAV technology works through the highly selective, replicative and safe oncolytic effect of NDV in humans.  The proprietary NDV strain specifically targets cancerous cells and then replicates itself, creating progeny viruses, which then target and infect other nearby as we well as distal cancerous cells (metastases) throughout the body.

NADAV appears to work by:

  1. Causing cell death of the infected tumor cells

  2. Triggering the host’s immune response towards the cancerous cells, by activating the anti-tumoral immune response.

This powerful oncolytic amplification effect is achieved with very low toxicity because NADAV specifically destroys the tumor cells and does not attack normal tissues.

Harnessing NADAV’s natural cancer fighting ability

ViruCure’s NADAV platform utilizes proprietary Newcastle Disease Virus (NDV) strains.

NADAV is a virus that causes different levels of infections in many kinds of birds. Yet in over 40 years of research, NADAV virus strains were found not to exhibit any pathological effects or severe illnesses in humans.  This combined with its high selectivity to replicate much faster in human cancer cells than normal human cells beyond the initial therapeutic dose, suggests the NADAV technology could be a breakthrough treatment modality as a highly safe and effective cancer therapy.

NADAV technology: Dual-acting mechanism of action

The NADAV technology works through the highly selective, replicative and safe oncolytic effect of NDV in humans.  The proprietary NDV strain specifically targets cancerous cells and then replicates itself, creating progeny viruses, which then target and infect other nearby as  well as distal cancerous cells (metastases) throughout the body.

NADAV appears to work by:

  1. Causing cell death of the infected tumor cells

  2. Triggering the host’s immune response towards the cancerous cells, by activating the anti-tumoral immune response.

This powerful oncolytic amplification effect is achieved with very low toxicity because NADAV specifically destroys the tumor cells and does not attack normal tissues.

NADAV Technology advantages

Highly targeted

Various mechanisms of action both at the cellular and extracellular level create a natural preference for tumor cells, preventing it from attacking healthy cells.

Amplification effect

Unlike most current gold standard cancer treatments, in pre-clinical trials NADAV showed replication beyond the initial therapeutic dose, spreading to metastases.

Double-effect

NADAV both destroys tumor cells and activates the immune system to kill cancer cells that would normally be hidden from it.

Non-human

NDVs natural hosts are birds meaning:

Humans do not have antibodies against NADAV that could reduce the oncolytic effectiveness.
During Phase 1/2 trials, patients did not develop major side effects during the course of treatment.